|
|
|
|
Science Sparks @ ACTREC
|
 25th April 2022 |
Vol. No. 11; Issue No. 523 |
|
|
Publications
|
|
1. Puja R, Chakraborty A, Dutta S, Bose K (2022). Purification, characterization and functional site prediction of the vaccinia-related kinase 2A small transmembrane domain. MethodsX.
2. Ranjan N, Chopra S, Mangaj A, Rane P, Charnalia M, Kannan S, Dora T, Engineer R, Mahantshetty U, Gurram L, Mittal P, Ghosh J, Maheshwari A, Shylasree TS, Gupta S, Shrivastava SK (2022). Months and severity score (MOSES) in a phase III trial (PARCER): A new comprehensive method for reporting adverse events in oncology clinical trials. eClinicalMedicine. 47: 101390.
3. Punatar S, Katti K, Rajamanickam D, Patil P, Dhakan C, Bagal B, Gokarn A, Bonda A, Nayak L, Gurjar M, Kannan S, Chiplunkar S, Gota V, Khattry N (2022). Role of curcumin in reducing toxicities associated with mucosal injury following melphalan-based conditioning in autologous transplant setting. Cell Transplantation.
4. Gandhi KA, Joshi A, Mehta P, Gurjar M, Rane P, Sharma J, Patil A, Nookala M, Noronha V, Prabhash K, Gota V (2022). Feasibility of therapeutic drug monitoring of sunitinib and its implications on response and toxicity in patients with metastatic renal cell cancer. Cancer Chemotherapy Pharmacology.
5. Pramesh CS, Badwe RA, Bhoo-Pathy N, Booth CM, Chinnaswamy G, Dare AJ, de Andrade VP, Hunter DJ, Gopal S, Gospodarowicz M, Gunasekera S, Ilbawi A, Kapambwe S, Kingham P, Kutluk T, Lamichhane N, Mutebi M, Orem J, Parham G, Ranganathan P, Sengar M, Sullivan R, Swaminathan S, Tannock IF, Tomar V, Vanderpuye V, Varghese C, Weiderpass E (2022). Priorities for cancer research in low- and middle-income countries: A global perspective. Nature Medicine. 28(4):649-657.
6. Poddar P, Maheshwari A, Shylasree TS, Yadav S, Kannan S, Ghosh J, Gullia S, Rath S, Chopra S, Gurram L, Gupta S (2022). Knowledge, attitudes and practices towards COVID-19: A cross-sectional survey. Indian Journal of Gynecologic Oncology. 20(2): 23.
|
|
|
|
|
Interesting Reads
|
|
Nelson JK, Thin MZ, Evan T, Howell S, Wu M, Almeida B, Legrave N, Koenis DS, Koifman G, Sugimoto Y, Llorian Sopena M, MacRae J, Nye E, Howell M, Snijders AP, Prachalias A, Zen Y, Sarker D, Behrens A. USP25 promotes pathological HIF-1-driven metabolic reprogramming and is a potential therapeutic target in pancreatic cancer. Nat Commun. 13(1): 2070, 2022.
|
|
|
Legends of Science
|
|
Sudhir Kumar Sopory
Sudhir Kunar Sopory obtained his Ph.D. from Delhi University in 1973. His notable contribution was to the mechanism of light and stress regulation of gene expression. Dr. Sopory has done significant work in the field of physiology of plant growth and development. His research has led to a better understanding of the mode of action of phytochrome and the possible involvement of calcium as a second messenger in higher plant cells. He is a member of several DBT, DST, CSIR, and UGC national committees. He was Vice Presient, INSA. Dr. Sopory was awarded the SS Bhatnagar award in 1987; ISCA Birbal Sahni Birth Centenary Award in 2006; Padma Shri in 2006. He was elected Fellow of the Indian Academy of Sciences, Bangalore; National Academy of Sciences, Allahabad; Academy of Sciences for the Developing World (TWAS).
|
|
| |
|
Mathur Ramabhadrashastry Narasimha Murthy
Mathur RN Murthy earned his Ph.D. from the Indian Institute of Science, Bangalore. Dr. Murthy and his group have worked out the three-dimensional structure of the Sesbania mosaic virus at 2.9 Å resolution by X-ray diffraction technique. His contributions have sharpened the understanding of how the complex molecular assemblies are put together in viruses. He is a Fellow of the Indian Academy of Sciences, Bangalore and National Academy of Sciences, Allahabad. Dr. Murthy is a recipient of the S S Bhatnagar Award in 1993; Rustom Choksi Award in 2002, and J C Bose Award in 2005.
|
|
| |
|
|
|
|
Do You Know?
In 2007, The FDA approved Nexavar (sorafenib) for primary liver cancer, making it the only drug approved for liver cancer.
|
|
|
|
|
|
� 2022 Advanced Centre for Treatment, Research and Education in Cancer (ACTREC)
|
|
